OTCMKTS:HNSBF - Hansa Biopharma AB (publ) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.20
+0.30 (1.20%)

This chart shows the closing price for HNSBF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hansa Biopharma AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HNSBF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HNSBF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Hansa Biopharma AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.20.

This chart shows the closing price for HNSBF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Hansa Biopharma AB (publ).

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/13/2021Royal Bank of CanadaReiterated RatingOutperform
6/23/2021HC WainwrightInitiated CoverageBuy
6/1/2021Royal Bank of CanadaReiterated RatingOutperform
4/26/2021DanskeInitiated CoverageBuy
7/7/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Hansa Biopharma AB (publ) logo
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme that is in Phase II for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Read More

Today's Range

Now: $18.20
Low: $18.20
High: $18.20

50 Day Range

MA: $18.20
Low: $18.20
High: $18.20

52 Week Range

Now: $18.20
Low: $16.40
High: $18.20

Volume

N/A

Average Volume

4,667 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hansa Biopharma AB (publ)?

The following Wall Street analysts have issued research reports on Hansa Biopharma AB (publ) in the last twelve months: Danske, HC Wainwright, and Royal Bank of Canada.
View the latest analyst ratings for HNSBF.

What is the current price target for Hansa Biopharma AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Hansa Biopharma AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hansa Biopharma AB (publ) in the next year.
View the latest price targets for HNSBF.

What is the current consensus analyst rating for Hansa Biopharma AB (publ)?

Hansa Biopharma AB (publ) currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HNSBF will outperform the market and that investors should add to their positions of Hansa Biopharma AB (publ).
View the latest ratings for HNSBF.

What other companies compete with Hansa Biopharma AB (publ)?

Other companies that are similar to Hansa Biopharma AB (publ) include Acacia Pharma Group, Biofrontera, BiomXInc ., China Medical System, Eco Animal Health, Innovent Biologics, Medivir AB (publ), Merck KGaA and Newscope Capital.

How do I contact Hansa Biopharma AB (publ)'s investor relations team?

Hansa Biopharma AB (publ)'s physical mailing address is Scheelevägen 22, Lund, Skane 223. The company's listed phone number is 46 46 16 56 70. The official website for Hansa Biopharma AB (publ) is www.hansabiopharma.com.